Kymera Poised to Become Leading Firm in Multiple Inflammation & Immunology Indications, RBC Says

MT Newswires Live12-17

Kymera Therapeutics (KYMR) is poised to become a leading company in multiple inflammation and immunology indications, with upside for further stock momentum, RBC Capital Markets said in a Tuesday note.

The company's early phase 1b results for its KT-621 trial surpassed RBC analysts' high expectations, and several days after the data in atopic dermatitis were released, investors mostly agree that it met almost all of the endpoints, the analysts said. They added that the strong early results reduce the negative risks of becoming an oral drug alternative.

The drug demonstrated potential effects on biomarkers related to other type-2 inflammation diseases aside from atopic dermatitis, the analysts noted. After its planned phase 2b trial on dose ranging, the company could potentially target other diseases apart from atopic dermatitis and asthma, notably eosinophilic chronic obstructive pulmonary disease, which could generate an estimated $1.3 billion opportunity in the US, the analysts said.

RBC adjusted its probability of success estimates for Kymera's atopic dermatitis and asthma programs and integrated an additional probability-adjusted indication for the drug candidate, resulting in an updated estimate potential peak US sales of $6.2 billion.

RBC maintained the company's stock rating at outperform and raised the price target to $103 from $70.

Price: 85.31, Change: -0.38, Percent Change: -0.44

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592936240?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-17 00:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592936240","market":"sh","top_or_hot":-1,"title":"Kymera Poised to Become Leading Firm in Multiple Inflammation & Immunology Indications, RBC Says","media":"MT Newswires Live","content":"<html><body><p> Kymera <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (KYMR) is poised to become a leading company in multiple inflammation and immunology indications, with upside for further stock momentum, RBC Capital Markets said in a Tuesday note.</p><p>The company's early phase 1b results for its KT-621 trial surpassed RBC analysts' high expectations, and several days after the data in atopic dermatitis were released, investors mostly agree that it met almost all of the endpoints, the analysts said. They added that the strong early results reduce the negative risks of becoming an oral drug alternative.</p><p>The drug demonstrated potential effects on biomarkers related to other type-2 inflammation diseases aside from atopic dermatitis, the analysts noted. After its planned phase 2b trial on dose ranging, the company could potentially target other diseases apart from atopic dermatitis and asthma, notably eosinophilic chronic obstructive pulmonary disease, which could generate an estimated $1.3 billion opportunity in the US, the analysts said.</p><p>RBC adjusted its probability of success estimates for Kymera's atopic dermatitis and asthma programs and integrated an additional probability-adjusted indication for the drug candidate, resulting in an updated estimate potential peak US sales of $6.2 billion.</p><p>RBC maintained the company's stock rating at outperform and raised the price target to $103 from $70.</p><p>Price: 85.31, Change: -0.38, Percent Change: -0.44</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kymera Poised to Become Leading Firm in Multiple Inflammation & Immunology Indications, RBC Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKymera Poised to Become Leading Firm in Multiple Inflammation & Immunology Indications, RBC Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-17 00:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Kymera <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (KYMR) is poised to become a leading company in multiple inflammation and immunology indications, with upside for further stock momentum, RBC Capital Markets said in a Tuesday note.</p><p>The company's early phase 1b results for its KT-621 trial surpassed RBC analysts' high expectations, and several days after the data in atopic dermatitis were released, investors mostly agree that it met almost all of the endpoints, the analysts said. They added that the strong early results reduce the negative risks of becoming an oral drug alternative.</p><p>The drug demonstrated potential effects on biomarkers related to other type-2 inflammation diseases aside from atopic dermatitis, the analysts noted. After its planned phase 2b trial on dose ranging, the company could potentially target other diseases apart from atopic dermatitis and asthma, notably eosinophilic chronic obstructive pulmonary disease, which could generate an estimated $1.3 billion opportunity in the US, the analysts said.</p><p>RBC adjusted its probability of success estimates for Kymera's atopic dermatitis and asthma programs and integrated an additional probability-adjusted indication for the drug candidate, resulting in an updated estimate potential peak US sales of $6.2 billion.</p><p>RBC maintained the company's stock rating at outperform and raised the price target to $103 from $70.</p><p>Price: 85.31, Change: -0.38, Percent Change: -0.44</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KYMR","symbol_name":"Kymera Therapeutics, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2592936240","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592936240","pubTimestamp":1765904262,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Kymera Therapeutics (KYMR) is poised to become a leading company in multiple inflammation and immunology indications, with upside for further stock momentum, RBC Capital Markets said in a Tuesday note","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KYMR":"Kymera Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"加拿大皇家银行表示，Kymera有望成为多种炎症和免疫学适应症的领先公司","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KYMR":1},"content_text":"Kymera Therapeutics (KYMR) is poised to become a leading company in multiple inflammation and immunology indications, with upside for further stock momentum, RBC Capital Markets said in a Tuesday note.The company's early phase 1b results for its KT-621 trial surpassed RBC analysts' high expectations, and several days after the data in atopic dermatitis were released, investors mostly agree that it met almost all of the endpoints, the analysts said. They added that the strong early results reduce the negative risks of becoming an oral drug alternative.The drug demonstrated potential effects on biomarkers related to other type-2 inflammation diseases aside from atopic dermatitis, the analysts noted. After its planned phase 2b trial on dose ranging, the company could potentially target other diseases apart from atopic dermatitis and asthma, notably eosinophilic chronic obstructive pulmonary disease, which could generate an estimated $1.3 billion opportunity in the US, the analysts said.RBC adjusted its probability of success estimates for Kymera's atopic dermatitis and asthma programs and integrated an additional probability-adjusted indication for the drug candidate, resulting in an updated estimate potential peak US sales of $6.2 billion.RBC maintained the company's stock rating at outperform and raised the price target to $103 from $70.Price: 85.31, Change: -0.38, Percent Change: -0.44","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592936240","isCrawlerRequest":true}